Anthea Wirges is Co-Founder and CEO of CARTemis Therapeutics. Since joining the Max Delbrück Center in Berlin as a PhD and later as a PostDoc, she has nearly ten years of experience in the immuno-oncology field with emphasis on improving the therapeutic outcome of CAR T cell therapy. Her work resulted in the invention and patenting of the cytoltyic enhancer technology to boost T cell efficacy. Anthea holds a degree in biochemistry and molecular biology from the University of Jena.
Login or Register
You need to be logged in to use this feature.
Further Activities to have a look at